Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1, a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27.